Payment overview · 2025
General Payments
$5,333.48
118 reported records · 25 companies
Healthcare provider profile · identity verified
Maged Answer Amine, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · HOUSTON, TX · NPI 1639161011
Verified facts
What the public records show
CMS Open Payments records show Maged Answer Amine, MD received $5,333.48 in general payments during 2025 across 118 reported records.
Cagent Vascular INC accounted for 48.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Verquvo.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $2,589.34 | 48.5% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $473.76 | 8.9% | 14 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.35 | 3.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $200.23 | 3.8% | 15 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $192.80 | 3.6% | 12 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $172.20 | 3.2% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$170.28 | 3.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.16 | 3.0% | 9 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $150.46 | 2.8% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $117.88 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $116.11 | 2.2% | 5 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $112.04 | 2.1% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $111.66 | 2.1% | 5 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $87.01 | 1.6% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $83.46 | 1.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.99 | 1.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.76 | 1.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.49 | 1.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $51.73 | 1.0% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $37.39 | 0.7% | 2 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $27.72 | 0.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $18.11 | 0.3% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.03 | 0.3% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $14.56 | 0.3% | 1 | 2025 |
| Argentum Medical | Unresolved — no canonical attribution shown | $11.96 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,257.31 | 114 |
| Travel and Lodging | $2,064.21 | 3 |
| Entertainment | $11.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $2,589.34 | 10 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $301.87 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $200.23 | 15 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $172.20 | 7 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $150.46 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $150.46 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $144.05 | 9 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $142.40 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $117.88 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $112.04 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $111.66 | 5 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $111.66 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $106.65 | 6 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $94.93 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $88.59 | 5 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $87.01 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $83.46 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $76.99 | 5 | 2025 |
Source payment records
|
|||||
| CONFIRM RX Normalized: confirm rx |
Device | Abbott Laboratories | $76.96 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.57 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $51.73 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.16 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $22.28 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $5.60 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 311 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
311 | 74 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
210 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
311 | 74 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 421 | 138 |
| Losartan Potassium | Losartan Potassium | 361 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 119 |
| Eliquis | Apixaban | 311 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 279 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 243 | 90 |
| Amiodarone Hcl | Amiodarone Hcl | 221 | 83 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 213 | 66 |
| Entresto | Sacubitril/Valsartan | 210 | 49 |
| Lisinopril | Lisinopril | 206 | 83 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 201 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 79 |
| Furosemide | Furosemide | 172 | 64 |
| Carvedilol | Carvedilol | 170 | 62 |
| Nebivolol Hcl | Nebivolol Hcl | 168 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 48 |
| Ezetimibe | Ezetimibe | 97 | 37 |
| Xarelto | Rivaroxaban | 96 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 24 |
| Farxiga | Dapagliflozin Propanediol | 63 | 21 |
| Nitroglycerin | Nitroglycerin | 50 | 32 |
| Nifedipine Er | Nifedipine | 48 | 17 |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 12 |
| Atenolol | Atenolol | 31 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Clonidine | Clonidine | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | 13 |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,333.48 · 118 records | Cagent Vascular INC | AMVUTTRA, AURYON LASER SYSTEM 100-120 VAC, AZURE XT DR MRI SURESCAN, Assure WCD, Barostim Neo System, BodyGuardian, CAMZYOS, CARDIOMEMS, CONFIRM RX, ELIQUIS, FUROSCIX, Flexitouch Plus, Hillrom - Carnation Ambulatory Monitor, JARDIANCE, JOT DX, LEQVIO, LINQ II, LUX-Dx Insertable Cardiac Monitor, LifeVest, MICRA, NURTEC ODT, Nimbl, OPSUMIT, Optimizer, Ozempic, REPATHA, Rybelsus, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, UPTRAVI, VERQUVO, VYNDAQEL, Venovo, WATCHMAN, WATCHMAN FLX, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error